Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 13, Number 7—July 2007

Research

Antiretroviral Therapy during Tuberculosis Treatment and Marked Reduction in Death Rate of HIV-Infected Patients, Thailand1

Somsak Akksilp*, Opart Karnkawinpong*, Wanpen Wattanaamornkiat*, Daranee Viriyakitja†, Patama Monkongdee‡, Walya Sitti*, Dhanida Rienthong†, Taweesap Siraprapasiri†‡, Charles D. Wells§, Jordan W. Tappero‡§, and Jay K. Varma†§Comments to Author 
Author affiliations: *Ministry of Public Health, Ubon-ratchathani, Thailand; †Ministry of Public Health, Nonthaburi, Thailand; ‡Thailand Ministry of Public Health–Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand; §Centers for Disease Control and Prevention, Atlanta, Georgia, USA;

Main Article

Table 4

Multivariate analysis of risk factors for death among HIV-infected TB patients with outcomes of cured, completed, failed, or died and adjusted for site of treating facility,* Ubon-ratchathani, February 2003 through January 2004†

CharacteristicAdjusted OR (95% CI)
Antiretroviral therapy before or during TB treatment0.2 (0.1–0.5)
Co-trimoxazole during TB treatment1.1 (0.6–2.3)
CD4 count (cells/mm3)
>200Referent
100–1995.5 (0.6–52.6)
50–999.3 (1.0–82.9)
<509.7 (1.2–78.4)
Unknown29.9 (3.8–238.0)
Type, location of TB
Sputum smear–positive, pulmonaryReferent
Sputum smear–negative, pulmonary1.3 (0.7–2.6)
Extrapulmonary0.5 (0.2–1.0)

*Data not shown.
†TB, tuberculosis; OR, odds ratio; CI, confidence interval.

Main Article

Data from this manuscript have been presented in part at the 36th UNION World Conference on Lung Health, Paris, October 2005, and the 15th Annual International AIDS Conference, Bangkok, July 2004.

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO